Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension

Journal of Human Hypertension

Volumn 19, Issue 8, 2005, Pages 629-633

  Curgunlu A ^a,b   Uzun, H ^a   Bavunoglu I ^a   Karter, Y ^a   Genc H ^a   Vehid, S ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

ADMA; White coat hypertension

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SMOKING HABIT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WHITE COAT HYPERTENSION;

ADULT; ARGININE; BLOOD PRESSURE MONITORING, AMBULATORY; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; OFFICE VISITS;

EID: 23644443687     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001867     Document Type: Article

References (43)

1. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 1995; 38: 105-128.
2. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
3. O'Driscoll G et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997; 100: 678-684.
4. Heitzer T et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 1996; 93: 1346-1353.
5. Tawakol A et al. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-1121.
6. Felmeden DC et al. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16: 11-20.
7. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41-51.
8. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-2037.
9. Surdacki A et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658.
10. Takiuchi S et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004; 17: 802-808.
11. Böger RH et al. Asymmetric dimethylarginine (ADMA) a novel risk factor for endothelial dysfunction its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.
12. Sydow K et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocysteinemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57: 244-252.
13. Valkonen VP et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.
14. Soma J et al. Hemodynamics in white coat hypertension compared to ambulatory hypertension and normotension. Am J Hypertens 1996; 9: 1090-1098.
15. Pickering TG et al. How common is white coat hypertension. JAMA 1988; 259: 225-228.
16. Cardillo C et al. Psychological reactivity and cardiac end organ changes in white coat hypertension. Hypertension 1993; 21: 836-844.
17. Hoegholm A et al. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension and normotension. Hypertension 1994; 24: 101-105.
18. Pierdomenico SD et al. Endothelial function in sustained and white coat hypertension. Am J Hypertens 2002; 15: 946-952.
19. Karter Y et al. Endothelium and angiogenesis in white coat hypertension. J Hum Hypertens 2004; 18: 809-814.
20. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207-209.
21. O'Brien E, Waeber B, Parati G, Staessen J, Myers MJ on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322: 531-536.
22. O'Brien E et al. Use and interpretation of Ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000; 320: 1128-1134.
23. 15N nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
24. Schulze F et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004; 42: 1377-1383.
25. Anderson TJ et al. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995; 75: 71-74.
26. Vanhouette PM. Endothelial dysfunction and atherosclerosis. Eur Heart J 1997; 18: 19-29.
27. Kinlay S et al. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension 2001; 38: 1049-1053.
28. Moriel P et al. Nitric oxide, cholesterol oxides and endothelium-dependent vasodilation in plasma of patients with essential hypertension. Braz J Med Biol Res 2002; 35: 1301-1309.
29. Julius S et al. 'White coat' versus 'sustained' borderline hypertension in Tecimseh, Michigan. Hypertension 1990; 16: 617-623.
30. Node K et al. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997; 30: 405-408.
31. Forte P et al. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349: 837-842.
32. Cardillo C et al. Selective defect in nitric synthesis may explain the impared endothelium-dependent vasodilatation in patients with hypertension. Circulation 1998; 97: 851-856.
33. Vallance P et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in renal failure. Lancet 1992; 339: 572-575.
34. Calver A et al. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 193-194.
35. Gomez CR et al. Noninvasive study of endothelial function in white coat hypertension. Hypertension 2002; 40: 304-309.
36. Karter Y et al. Target organ damage and changes in arterial compliance in white coat hypertension. Is white coat innocent? Blood Press 2003; 12: 307-313.
37. Vaindirlis I et al. 'White coat hypertension' in adolescents: increased values of urinary cortisol and endothelin. J Pediatr 2000; 136: 359-364.
38. Blann AD, Tse W, Maxwell SJR, Waite MA. Increased levels of soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 1994; 12: 925-928.
39. Verhaar MC et al. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J Hypertens 1998; 16: 45-50.
40. Chowdhary S, Townend JN. Nitric oxide and hypertension: not just an endothelium derived relaxing factor!. J Hum Hypertens 2001; 15: 219-227.
41. Smith PA et al. Sympathetic neural mechanisms in white coat hypertension. J Am Coll Cardiol 2002; 40: 126-132.
42. Smith PA et al. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 2004; 17: 217-222.
43. Osanai T et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endotehelial cells. Hypertension 2003; 42: 985-990.